Manufacturing Strength Leverage MeiraGTx’s vertically integrated, end-to-end manufacturing platform and GMP viral vector production facilities to position as a one-stop partner for early to late-stage gene therapy programs, reducing supply risk for potential collaborators.

Late-Stage Focus Target late-stage assets and near-term regulatory catalysts such as AAV2-hAQP1 and botaretigene sparoparvovec (bota-vec) where existing infrastructure can accelerate clinical development and potential commercial launches, appealing to partners seeking scale-ready programs.

Riboswitch Advantage Highlight the riboswitch gene regulation platform for dose-responsive control of gene expression, offering potential competitive differentiation for metabolic peptide delivery and combinatorial strategies with partner programs seeking controllable gene therapies.

Financial Solid Capitalize on a robust cash runway and recent strategic investment to de-risk collaborations, offering favorable terms, milestone structuring, and non-dilutive financing options to accelerate co-development and manufacturing partnerships.

Market Expansion Explore partnerships across eye, CNS, and salivary gland indications with potential to expand into larger disease areas, aligning MeiraGTx’s manufacturing and regulatory capabilities with partners pursuing high-need, large-market opportunities.